Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2

Interventions

veliparib 2tucatinib 2leronlimab 2abemaciclib 2Trastuzumab 2Capecitabine 2Alpelisib 2zenocutuzumab 1selpercatinib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1pegilodecakin 1palbociclib 1margetuximab 1iniparib 1glembatumumab vedotin 1gedatolisib 1eribulin 1Vinorelbine 1Proton Pump Inhibitors 1Letrozole 1Lapatinib 1Hydrocortisone 1Everolimus 1Cisplatin 1Ado-Trastuzumab Emtansine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × leronlimab × Breast × Clear all
NCT07536815 2026-04-27

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

CytoDyn, Inc.

Available
Breast

Triple Negative Breast Neoplasms

NCT04313075 2025-07-15

A Compassionate Use Study of Leronlimab in Breast Cancer

CytoDyn, Inc.

No longer available
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡